KR20200085815A - 과증식성 질병의 치료를 위한 카페인산 유도체 - Google Patents
과증식성 질병의 치료를 위한 카페인산 유도체 Download PDFInfo
- Publication number
- KR20200085815A KR20200085815A KR1020207015972A KR20207015972A KR20200085815A KR 20200085815 A KR20200085815 A KR 20200085815A KR 1020207015972 A KR1020207015972 A KR 1020207015972A KR 20207015972 A KR20207015972 A KR 20207015972A KR 20200085815 A KR20200085815 A KR 20200085815A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- compounds
- groups
- cancer
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584591P | 2017-11-10 | 2017-11-10 | |
| US62/584,591 | 2017-11-10 | ||
| PCT/US2018/059975 WO2019094689A1 (en) | 2017-11-10 | 2018-11-09 | Caffeic acid derivatives for treating hyperproliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200085815A true KR20200085815A (ko) | 2020-07-15 |
Family
ID=64664389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207015972A Ceased KR20200085815A (ko) | 2017-11-10 | 2018-11-09 | 과증식성 질병의 치료를 위한 카페인산 유도체 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10703721B2 (https=) |
| EP (1) | EP3707125A1 (https=) |
| JP (1) | JP7428642B2 (https=) |
| KR (1) | KR20200085815A (https=) |
| CN (1) | CN111417625A (https=) |
| AU (1) | AU2018366270B2 (https=) |
| BR (1) | BR112020009219A2 (https=) |
| CA (1) | CA3081975A1 (https=) |
| EA (1) | EA202091164A1 (https=) |
| MX (1) | MX2020004871A (https=) |
| SG (1) | SG11202004230XA (https=) |
| TW (1) | TWI846678B (https=) |
| UA (1) | UA126821C2 (https=) |
| WO (1) | WO2019094689A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12539503B2 (en) | 2022-08-03 | 2026-02-03 | The University Of Toledo | Environmentally friendly polymeric sorbent material for the extraction and determination of rare earth elements, thorium, and uranium |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL119069A0 (en) | 1996-08-14 | 1996-11-14 | Mor Research Applic Ltd | Pharmaceutical composition comprising tyrphostins |
| WO2003068157A2 (en) | 2002-02-11 | 2003-08-21 | The Brigham And Women's Hospital, Inc. | Kinase inhibitors and methods of use thereof |
| PT1701941E (pt) | 2003-12-11 | 2012-08-03 | Univ Texas | Compostos para o tratamento de doenças proliferativas celulares |
| BRPI0709916B8 (pt) | 2006-03-31 | 2021-05-25 | Univ Texas | drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas |
| WO2008005954A2 (en) | 2006-06-30 | 2008-01-10 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
| NZ590372A (en) * | 2008-07-08 | 2012-09-28 | Univ Texas | Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats) |
| US20130129675A1 (en) | 2009-12-04 | 2013-05-23 | Board Of Regents, The University Of Texas System | Interferon therapies in combination with blockade of stat3 activation |
| EP2619184B1 (en) | 2010-09-24 | 2018-05-23 | The Regents of the University of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| US9868736B2 (en) | 2013-10-10 | 2018-01-16 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| WO2015183987A1 (en) | 2014-05-27 | 2015-12-03 | Pharmakea, Inc. | Compositions and methods of delivery of deubiquitinase inhibitors |
| CA2948883A1 (en) * | 2014-06-02 | 2015-12-10 | Pharmakea, Inc. | Deubiquitinase inhibitors |
-
2018
- 2018-11-08 TW TW107139731A patent/TWI846678B/zh active
- 2018-11-09 KR KR1020207015972A patent/KR20200085815A/ko not_active Ceased
- 2018-11-09 US US16/185,669 patent/US10703721B2/en active Active
- 2018-11-09 EP EP18816306.7A patent/EP3707125A1/en active Pending
- 2018-11-09 JP JP2020525946A patent/JP7428642B2/ja active Active
- 2018-11-09 MX MX2020004871A patent/MX2020004871A/es unknown
- 2018-11-09 CA CA3081975A patent/CA3081975A1/en active Pending
- 2018-11-09 EA EA202091164A patent/EA202091164A1/ru unknown
- 2018-11-09 WO PCT/US2018/059975 patent/WO2019094689A1/en not_active Ceased
- 2018-11-09 UA UAA202003449A patent/UA126821C2/uk unknown
- 2018-11-09 SG SG11202004230XA patent/SG11202004230XA/en unknown
- 2018-11-09 AU AU2018366270A patent/AU2018366270B2/en not_active Ceased
- 2018-11-09 CN CN201880077894.0A patent/CN111417625A/zh active Pending
- 2018-11-09 BR BR112020009219-3A patent/BR112020009219A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019094689A1 (en) | 2019-05-16 |
| MX2020004871A (es) | 2020-08-06 |
| EP3707125A1 (en) | 2020-09-16 |
| JP2021502374A (ja) | 2021-01-28 |
| TWI846678B (zh) | 2024-07-01 |
| UA126821C2 (uk) | 2023-02-08 |
| CN111417625A (zh) | 2020-07-14 |
| AU2018366270A1 (en) | 2020-05-21 |
| CA3081975A1 (en) | 2019-05-16 |
| AU2018366270B2 (en) | 2023-04-20 |
| TW201922707A (zh) | 2019-06-16 |
| US20190177276A1 (en) | 2019-06-13 |
| JP7428642B2 (ja) | 2024-02-06 |
| SG11202004230XA (en) | 2020-06-29 |
| BR112020009219A2 (pt) | 2020-10-20 |
| EA202091164A1 (ru) | 2020-08-03 |
| US10703721B2 (en) | 2020-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102536408B1 (ko) | Hsp90 저해제 및 hsp70 유도제로서의 개질된 에터기를 가진 바이페닐 아마이드 | |
| RU2686323C2 (ru) | Новые соединения и композиции для ингибирования fasn | |
| EP2643300A1 (en) | Inhibitors of the activity of complex iii of the mitochondrial electron transport chain and use thereof for treating diseases | |
| JP7794910B2 (ja) | Ｅａａｔ２活性化因子およびその使用方法 | |
| KR100602977B1 (ko) | 안트라닐산 아미드 및 ｖｅｇｆ 수용체 티로신 키나제억제제로서 그의 용도 | |
| JP6637890B2 (ja) | ベンズアミド及びニコチンアミド化合物及びこれを使用する方法 | |
| CN103992236A (zh) | 一种新型靶向性抗肿瘤药物及其制备方法与应用 | |
| SA109300394B1 (ar) | ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها | |
| JP6542236B2 (ja) | 有機化合物 | |
| KR20200085815A (ko) | 과증식성 질병의 치료를 위한 카페인산 유도체 | |
| CN107072970A (zh) | 用于治疗癌症和其他增殖性疾病的新的辣椒平类似物 | |
| TW200906831A (en) | Kinase inhibitor | |
| WO2017223514A9 (en) | Lxr inverse agonists for treatment of cancer | |
| CN121240859A (zh) | 用于治疗健康状况的组合物和制备和使用小分子的方法 | |
| WO2025189066A1 (en) | Modulators of g protein-coupled receptor 55 (gpr55) | |
| HK40042691A (en) | Eaat2 activators and methods of using thereof | |
| HK40042691B (en) | Eaat2 activators and methods of using thereof | |
| BR112016029672B1 (pt) | Composto bifenil amida com grupos éter modificados como inibidores de hsp90 e indutores de hsp70, composição farmacêutica que compreende o dito composto, bem como uso terapêutico do mesmo | |
| HK1259495B (en) | Dna binding agents with a minor groove binding tail |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20200603 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20211108 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240222 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20240501 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20240222 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |